Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
29/08/2024 | 13:00 | GlobeNewswire Inc. | Arvinas to Participate in Upcoming Investor Conferences | NASDAQ:ARVN | Arvinas Inc |
20/08/2024 | 22:16 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ARVN | Arvinas Inc |
30/07/2024 | 13:00 | GlobeNewswire Inc. | Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:ARVN | Arvinas Inc |
22/07/2024 | 14:30 | GlobeNewswire Inc. | HOOKIPA Pharma Announces Leadership Changes to Intensify Focus on HB-200 | NASDAQ:ARVN | Arvinas Inc |
24/06/2024 | 22:37 | GlobeNewswire Inc. | Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer | NASDAQ:ARVN | Arvinas Inc |
21/06/2024 | 13:00 | GlobeNewswire Inc. | Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2 | NASDAQ:ARVN | Arvinas Inc |
18/06/2024 | 23:53 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:ARVN | Arvinas Inc |
18/06/2024 | 23:51 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:ARVN | Arvinas Inc |
17/06/2024 | 13:00 | GlobeNewswire Inc. | Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer | NASDAQ:ARVN | Arvinas Inc |
23/05/2024 | 23:00 | GlobeNewswire Inc. | Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress | NASDAQ:ARVN | Arvinas Inc |
16/05/2024 | 12:00 | GlobeNewswire Inc. | Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) | NASDAQ:ARVN | Arvinas Inc |
09/05/2024 | 22:42 | GlobeNewswire Inc. | Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress | NASDAQ:ARVN | Arvinas Inc |
07/05/2024 | 22:13 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ARVN | Arvinas Inc |
07/05/2024 | 13:00 | GlobeNewswire Inc. | Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update | NASDAQ:ARVN | Arvinas Inc |
02/05/2024 | 13:00 | GlobeNewswire Inc. | Arvinas to Present at Upcoming Investor Conferences | NASDAQ:ARVN | Arvinas Inc |
24/04/2024 | 22:30 | GlobeNewswire Inc. | Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer | NASDAQ:ARVN | Arvinas Inc |
11/04/2024 | 13:00 | GlobeNewswire Inc. | Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer | NASDAQ:ARVN | Arvinas Inc |
18/03/2024 | 21:40 | GlobeNewswire Inc. | Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer | NASDAQ:ARVN | Arvinas Inc |
27/02/2024 | 22:46 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:ARVN | Arvinas Inc |
27/02/2024 | 13:00 | GlobeNewswire Inc. | Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update | NASDAQ:ARVN | Arvinas Inc |
20/02/2024 | 22:05 | GlobeNewswire Inc. | Arvinas Announces Chief Financial Officer Transition | NASDAQ:ARVN | Arvinas Inc |
20/02/2024 | 13:00 | GlobeNewswire Inc. | Arvinas Announces First-in-Human Dosing of ARV-102, an Investigational PROTAC® Protein Degrader for Neurodegenerative Disease | NASDAQ:ARVN | Arvinas Inc |
14/02/2024 | 14:00 | GlobeNewswire Inc. | Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer | NASDAQ:ARVN | Arvinas Inc |
14/02/2024 | 02:14 | Edgar (US Regulatory) | Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] | NASDAQ:ARVN | Arvinas Inc |
06/02/2024 | 12:45 | GlobeNewswire Inc. | Arvinas and Pfizer’s Vepdegestrant (ARV-471) Receives FDA Fast Track Designation for the Treatment of Patients with ER+/HER2- Metastatic Breast Cancer | NASDAQ:ARVN | Arvinas Inc |
01/02/2024 | 22:30 | GlobeNewswire Inc. | Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference | NASDAQ:ARVN | Arvinas Inc |
16/01/2024 | 23:01 | GlobeNewswire Inc. | Arvinas Appoints Jared Freedberg as General Counsel | NASDAQ:ARVN | Arvinas Inc |
16/01/2024 | 22:03 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:ARVN | Arvinas Inc |
08/12/2023 | 15:16 | Edgar (US Regulatory) | Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers | NASDAQ:ARVN | Arvinas Inc |
06/12/2023 | 04:52 | GlobeNewswire Inc. | Arvinas to Host Conference Call and Webcast to Discuss Vepdegestrant (ARV-471) Data Presented at 2023 San Antonio Breast Cancer Symposium and Plans to Expand Vepdegestrant Development Program | NASDAQ:ARVN | Arvinas Inc |